Modified GRF (1–29) / Ipamorelin / GHRP-2 Blend is a research peptide formulation combining three well-studied synthetic peptides commonly examined in growth hormone and endocrine signaling research: Modified GRF (1–29), Ipamorelin, and Growth Hormone–Releasing Peptide-2 (GHRP-2). Modified GRF (1–29) is a stabilized analog of growth hormone–releasing hormone (GHRH), while Ipamorelin and GHRP-2 are growth hormone secretagogue receptor (GHS-R) agonists with differing receptor activity profiles. Together, this blend is formulated for laboratory research focused on growth hormone pulsatility, receptor signaling pathways, and coordinated endocrine response mechanisms.
Prior to the targeted synthesis and study of these peptides, research into growth hormone modulation relied largely on less selective secretagogues and broader hormonal interventions. In controlled research settings, Modified GRF (1–29) has been studied for its ability to stimulate endogenous growth hormone release through GHRH receptor activation while maintaining a short duration of activity. Ipamorelin has been examined for its selective receptor activity and minimal interaction with other pituitary hormones, while GHRP-2 has been widely researched for its potent receptor binding and influence on growth hormone secretion dynamics. The combination allows researchers to examine complementary mechanisms involved in growth hormone release amplitude, frequency, and signaling coordination.
Currently, the Modified GRF (1–29) / Ipamorelin / GHRP-2 Blend is being investigated for potential applications in metabolic research models, endocrine pathway analysis, recovery-related signaling studies, and age-associated hormone regulation research. Additional investigation continues into its role in downstream anabolic signaling, circadian hormone release patterns, and integrated pituitary response mechanisms. Due to the complementary research interest of these peptides, this blend remains a compelling subject for ongoing laboratory investigation.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
The Modified GRF (1-29), Ipamorelin, GHRP-2 Blend is structured for laboratory research investigating growth hormone signaling pathways, endocrine communication within the hypothalamic–pituitary axis, and downstream metabolic biomarker responses. By combining a growth hormone–releasing hormone analog with two growth hormone secretagogues, this peptide blend allows researchers to examine how multiple GH-axis signaling inputs interact within controlled experimental models.
Multi-peptide experimental designs are commonly used to evaluate pathway interactions and hormone response behavior under defined laboratory conditions. These research models can help investigators analyze how pulsatile hormone release patterns respond when upstream GHRH signaling and ghrelin receptor–mediated pathways are activated simultaneously.
Modified GRF (1-29), Ipamorelin, GHRP-2 Blend – Research Specifications:
| Format | Lyophilized peptide blend (research format) |
| Contents | Modified GRF (1-29) + Ipamorelin + GHRP-2 |
| Purity / Identity | Research-grade; refer to Certificate of Analysis (COA) for lot-specific analytical data |
| Source | Peptide synthesis with standardized processing and QC documentation |
| Appearance | Powder (lyophilized) |
| Storage Conditions | Store sealed in a cool, dry environment protected from heat, light, and moisture. Maintain lot integrity per laboratory SOPs. |
| Research Use Only | Supplied exclusively for laboratory research use. Not for human consumption, clinical use, or veterinary applications. |
Modified GRF (1-29) is a growth hormone–releasing hormone analog studied in laboratory environments focused on hypothalamic–pituitary signaling and pulsatile GH release patterns. In controlled research settings, this compound is frequently used to investigate how upstream signaling influences hormone release dynamics.
Ipamorelin and GHRP-2 are growth hormone secretagogues that interact with ghrelin receptor pathways associated with pituitary hormone signaling. These peptides are frequently used in endocrine research models examining how secretagogue-driven stimulation influences growth hormone activity and downstream biomarker responses.
When these three peptides are combined in a laboratory protocol, researchers can examine how GHRH pathway stimulation interacts with ghrelin receptor–mediated signaling. Experimental models often monitor hormone pulse amplitude, frequency, and endocrine marker behavior across defined time intervals in order to understand pathway interaction effects.
Researchers interested in studying the peptides individually may reference the product pages for CJC-1295 (without DAC), Ipamorelin, and GHRP-2.
Important Research Notice: Nordsci products are supported by lot-level analytical documentation. Certificates of Analysis are available to support internal audits, method alignment, and reproducibility across research studies.
THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION. NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE OR CONDITION.
A primary research focus for this peptide blend is the study of pulsatile growth hormone release. Investigators may evaluate hormone signaling patterns by monitoring endocrine marker changes across controlled sampling intervals.
Because this blend activates both GHRH and ghrelin receptor signaling pathways, it provides a useful experimental model for examining communication within the hypothalamic–pituitary axis and how multiple signaling inputs affect hormone release behavior.
GH-axis research frequently includes downstream biomarker measurement to observe endocrine responses. Researchers may evaluate how hormone signaling fluctuations correspond with measurable biomarker changes under controlled laboratory conditions.
Many experimental protocols compare multi-peptide blends with single-compound research conditions. This allows investigators to determine whether observed signaling responses are driven by individual peptides or by interactions between multiple endocrine pathways.
The Modified GRF (1-29), Ipamorelin, GHRP-2 Blend should be handled according to standard peptide laboratory procedures emphasizing contamination prevention, proper storage conditions, and detailed experimental documentation. Stable laboratory conditions help improve reproducibility across research cohorts.
Protocol Design Considerations: Growth hormone signaling research is sensitive to circadian rhythm timing, metabolic baseline conditions, environmental variables, and experimental stress factors. Carefully controlled laboratory environments and standardized sampling windows help ensure reliable data interpretation.
Note: The information above is provided solely as a research reference summary. All experimental work must be conducted by qualified researchers in appropriate laboratory facilities.
Each lot of this peptide blend includes a Certificate of Analysis verifying peptide identity and quality parameters. These analytical reports support procurement verification, regulatory documentation, and reproducibility tracking across research programs.
Laboratories sourcing peptides for endocrine signaling research typically prioritize traceable documentation, consistent synthesis standards, and reliable quality-control processes. Nordsci Peptides provides research-grade peptide materials supported by analytical documentation and manufacturing standards designed to support reproducible laboratory research.
IMPORTANT: This product is supplied exclusively for laboratory research use. It is not approved for human consumption or clinical application. Researchers are responsible for ensuring compliance with all applicable regulatory and institutional guidelines.
